



C B M T | G 

Preliminary  
Conference Program

TORONTO  2012  
ONTARIO  
ANNUAL CONFERENCE  
APRIL 11-14, 2012

## CBMTG Preliminary Conference Program 2012

### PRE-CONFERENCE DAY: TUESDAY, APRIL 10, 2012

**1600 – 1900** CONFERENCE REGISTRATION

### PRE-CONFERENCE DAY: WEDNESDAY, APRIL 11, 2012

**0900 – 1900** CONFERENCE REGISTRATION

**0900 – 1200** CBMTG 0801 Investigator Meeting

#### Trainee Session

**0900 – 1200** *This session will be a BMT 101 session, providing an overview of landmark studies, historical retrospective of key achievements, and in-depth information of indications, treatments, protocols, complications, and stem cell harvest.*

**1300 – 1700** Nursing Session: Hot Topics in Transplant Nursing, Podium, and Panel Presentations

#### CBMTG Laboratory Committee Meeting

**1300 – 1700**

- Laboratory Committee Meeting
- ISBT128 – Developing an Implementation Plan
- BMT Program Review – St. John NB
- Proliferation / Potency Assays
- Environmental Monitoring

**1300 – 1700** Clinical Trials Network Meeting

**1930 – 2100** WELCOME RECEPTION WITH EXHIBITS

### DAY 1: THURSDAY, APRIL 12, 2012

**0700 – 1800** CONFERENCE REGISTRATION DESK OPEN

**0900 – 1645** Exhibits/Posters Open

**0700 – 0845** *BREAKFAST SYMPOSIUM: INDUSTRY SPONSORED EVENT, NON-ACCREDITED.*

#### Welcome from Conference Chairs

#### Session 1 – Canadian BMT State of Affairs

**0900 – 1015** *The session will begin with presentations from Drs. Armand Keating and Hans Messner, who will provide context for development of transplant in Canada and how we set the stage now. Dr. John Kuruvilla will then go over where we may see transplant in Canada over the coming years.*

**1015 – 1045** Break with Exhibits

**DAY 1: THURSDAY, APRIL 12, 2012** *continued*

<b>1045 – 1215</b>	<p><b>Session 2A: Hemoglobinopathies Transplantation</b></p> <ul style="list-style-type: none"> <li>• Sickle Cell Syndromes</li> <li>• Thalassemia</li> <li>• How to Perform a Safer Transplant</li> </ul>	<p><b>Session 2B: Chronic GVHD</b></p> <ul style="list-style-type: none"> <li>• Canadian Experience for Photopheresis in the Management of GVHD</li> <li>• A Practical Guide to the NIH Assessment of Chronic GVHD</li> <li>• How to Measure Quality of Life in Patients Post Stem Cell Transplant</li> </ul>	<p><b>Session 2C: Timing of Allo Transplant</b></p> <ul style="list-style-type: none"> <li>• CLL</li> <li>• MDS</li> <li>• Timing of Transplant in Normal Karyotype AML</li> </ul>	<p><b>Session 2D: Pharmacy Interaction Session</b></p> <ul style="list-style-type: none"> <li>• Can a Pharmacist, as Part of the Multi-disciplinary Team Improve Patient Medication Safety in the Allogeneic Transplant Ambulatory Clinic?</li> <li>• Drug-Drug Interaction</li> </ul>
<b>1230 – 1400 LUNCH SYMPOSIUM: INDUSTRY SPONSORED EVENT, NON-ACCREDITED.</b>				
<b>1415 – 1615 Session 3 – Science of Transplant</b> <i>The presentations in this session will focus on cancer stem cells and t-cell immunology.</i>				
<b>1615 – 1645 Break with Exhibits</b>				
<b>1645 – 1745 Session 4 – Hans Messner Lectureship</b> Best Practices: Long Term Follow Up Post Transplantation				

**DAY 2: FRIDAY, APRIL 13, 2012**

<b>0700 – 1915 CONFERENCE REGISTRATION DESK OPEN</b>				
<b>0700 – 0845 BREAKFAST SYMPOSIUM: INDUSTRY SPONSORED EVENT, NON-ACCREDITED.</b>				
<b>1030 – 1800 Posters/Exhibits Open</b>				
<b>0900 – 1100</b>	<p><b>Session 5A: Psychosocial Issues in Transplant</b></p> <ul style="list-style-type: none"> <li>• Survivorship</li> <li>• Psychosocial Issues among Caregivers of Transplant Recipients</li> <li>• Sexuality</li> </ul>	<p><b>Session 5B: Auto BMT /Myeloma</b></p> <ul style="list-style-type: none"> <li>• Aggressive Lymphoma</li> <li>• Myeloma</li> <li>• High Dose Therapy in the Management of CNS Lymphoma</li> </ul>	<p><b>Session 5C: Technical Issues/Transplant</b></p> <ul style="list-style-type: none"> <li>• CBS OneMatch Registry Update</li> <li>• CBS OneMatch Cord Blood Bank</li> <li>• FACT – Common Program Deficiencies</li> <li>• Update from Health Canada on Safety of Human Cells, Tissues and Organs for Transplantation Regulations</li> </ul>	<p><b>Session 5D: Mega Therapies for Brain Tumours</b></p>

**DAY 2: FRIDAY, APRIL 13, 2012** *continued*

**1100 – 1115** *Break with Exhibits*

**1115 – 1215** CBMTG Annual General Meeting

**1230 – 1400** *LUNCH SYMPOSIUM: INDUSTRY SPONSORED EVENT, NON-ACCREDITED.*

**1415 – 1700** Session 6: Abstract Presentations

**1700 – 1800** Session 7: Poster Presentations

**1900 – 2300** CBMTG Dinner and Awards

**DAY 3: SATURDAY, APRIL 14, 2012**

**0700 – 1600** CONFERENCE REGISTRATION DESK OPEN

**0700 – 0845** *BREAKFAST SYMPOSIUM: INDUSTRY SPONSORED EVENT, NON-ACCREDITED.*

**0900 – 1030** Session 8 – Acute Lymphoblastic Leukemia

*This Session will focus on management of pediatric ALL as well as drug therapy versus transplantation ALL.*

**1030 – 1045** *Break*

Session 9 – Lymphoma

- 1045 – 1215**
- Therapy of Transformed Indolent Lymphoma
  - BMT for Mantle Cell Lymphoma
  - BMT for T Cell Lymphoma

**1230 – 1400** *LUNCH SYMPOSIUM: INDUSTRY SPONSORED EVENT, NON-ACCREDITED.*

**1415 – 1545** Session 10 – Controversial Issues in BMT

*This Session will discuss the controversies in alternate donor transplants. The presentations will focus on issues encountered in haplo identical and cord blood transplants.*